GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ZP4207

Company
Zealand Pharma
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT02367053

    Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator

    Not yet reported Zealand Pharma 111 participants Est. completion 2015-04 1 site Stand-alone
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02390141

    Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207

    Not yet reported Zealand Pharma 24 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02660008

    Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon

    Not yet reported Zealand Pharma 81 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT02916251

    ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon

    Not yet reported Zealand Pharma 38 participants Est. completion 2017-04-05 1 site Stand-alone
    Other conditions: Diabetes Mellitus Type 1
    View official trial listing →
  • Completed NCT NCT02971228

    Feasibility Trial Testing the Bionic Pancreas With ZP4207

    Not yet reported Zealand Pharma 13 participants Est. completion 2017-06-07 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03216226

    A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus

    Not yet reported Zealand Pharma 112 participants Est. completion 2018-02-13 7 sites Stand-alone
    Other conditions: Hypoglycemia, Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03378635

    A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

    Not yet reported Zealand Pharma 170 participants Est. completion 2018-05-25 5 sites
    Other conditions: Hypoglycemia, Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03667053

    Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children

    Not yet reported Zealand Pharma 42 participants Est. completion 2019-06-28 5 sites
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT03688711

    Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

    Not yet reported Zealand Pharma 45 participants Est. completion 2019-03-11 3 sites
    Other conditions: Hypoglycemia, Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03735225

    Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

    Not yet reported Zealand Pharma 60 participants Est. completion 2019-06-24 1 site
    Other conditions: Hypoglycemia
    View official trial listing →
  • Completed NCT NCT03777176

    A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

    Not yet reported Zealand Pharma 32 participants Est. completion 2020-10-05 10 sites
    Other conditions: Congenital Hyperinsulinism
    View official trial listing →
  • Completed NCT NCT03895697

    A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM

    Not yet reported Zealand Pharma 92 participants Est. completion 2019-07-30 1 site
    Other conditions: Hypoglycemia, Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT03941236

    Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

    Not yet reported Zealand Pharma 42 participants Est. completion 2026-05-26 10 sites
    Other conditions: Congenital Hyperinsulinism
    View official trial listing →
  • Completed NCT NCT03984370

    Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

    Not yet reported University Hospital, Gentofte, Copenhagen 10 participants Est. completion 2020-02-26 1 site Stand-alone
    Other conditions: Hyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia
    View official trial listing →
  • Completed NCT NCT04172441

    Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

    Not yet reported, Not yet reported Zealand Pharma 12 participants Est. completion 2022-03-07 6 sites
    Other conditions: Congenital Hyperinsulinism
    View official trial listing →
  • Completed NCT NCT04836273

    Treatment of Post-bariatric Hypoglycaemia

    Not yet reported Filip Krag Knop 24 participants Est. completion 2022-12-15 1 site
    Other conditions: Hyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia
    View official trial listing →
  • Completed NCT NCT05378672

    A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

    Not yet reported Zealand Pharma 8 participants Est. completion 2024-12-03 2 sites
    Other conditions: Hypoglycemia, Type 1 Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: ZP4207, ZP4207 (dasiglucagon)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.